NASDAQ · IPSC
Century Therapeutics, Inc.
$1.47+$0.01 (+0.68%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.64% below the high.
Loading market information…
NASDAQ · ICCC · USD
Stock price, earnings
Quote as of Oct 30, 2026, 07:21 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ImmuCell Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ImmuCell Corporation’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of $0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ImmuCell Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:22 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 25, 2025 |
| $0.06 |
| $7.75M |
| Q3 2024 | Nov 13, 2024 | -$0.09 | $6.01M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.47+$0.01 (+0.68%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.64% below the high.
$20.17-$1.28 (-5.97%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.67% below the high.
$0.47-$0.03 (-5.31%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.6% below the high.
$2.25-$0.41 (-15.41%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.53% below the high.
$1.40-$0.02 (-1.41%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.45% below the high.
$1.90-$0.10 (-5.0%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.06% below the high.
$1.22-$0.08 (-6.03%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 45.71% below the high.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
